Arcturus Therapeutics’ (ARCT) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a report published on Friday morning,Benzinga reports. The firm currently has a $63.00 price objective on the biotechnology company’s stock.

ARCT has been the topic of a number of other research reports. BTIG Research assumed coverage on Arcturus Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $41.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Arcturus Therapeutics presently has an average rating of “Buy” and an average target price of $65.00.

Arcturus Therapeutics Price Performance

ARCT opened at $18.05 on Friday. The stock has a market cap of $488.97 million, a P/E ratio of -8.13 and a beta of 2.62. The stock’s 50 day simple moving average is $17.01 and its 200 day simple moving average is $18.92. Arcturus Therapeutics has a 1-year low of $14.30 and a 1-year high of $45.00.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Franklin Resources Inc. lifted its stake in shares of Arcturus Therapeutics by 54.6% during the 3rd quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock worth $2,412,000 after purchasing an additional 36,714 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Arcturus Therapeutics by 45.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock worth $52,819,000 after purchasing an additional 712,650 shares during the period. Empire Life Investments Inc. acquired a new stake in shares of Arcturus Therapeutics during the 3rd quarter worth $3,498,000. Hennion & Walsh Asset Management Inc. increased its holdings in shares of Arcturus Therapeutics by 139.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company’s stock worth $1,393,000 after buying an additional 47,824 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Arcturus Therapeutics during the 3rd quarter worth $191,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.